![](https://investorshub.advfn.com/uicon/479388.png?cb=1599729622)
Friday, December 06, 2019 8:24:19 AM
Recent SAGE News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 10:39:54 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 • Business Wire • 07/17/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:57:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:57:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:16:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 10:45:00 AM
- Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease • Business Wire • 06/11/2024 10:30:00 AM
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/05/2024 10:30:00 AM
- Sage Therapeutics to Participate in Upcoming May Investor Conferences • Business Wire • 05/07/2024 10:30:00 AM
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 04/25/2024 10:30:00 AM
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease • Business Wire • 04/17/2024 10:30:00 AM
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/11/2024 10:30:00 AM
- Sage Therapeutics to Present at Upcoming March Investor Conferences • Business Wire • 02/28/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/21/2024 09:35:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:02:15 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:09:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/14/2024 12:49:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/14/2024 12:20:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 11:45:53 AM
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 02/14/2024 11:30:00 AM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 01/31/2024 10:25:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:50:55 PM
- Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 • Business Wire • 01/31/2024 11:30:00 AM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM